Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.
Laurent C, Adélaïde J, Guille A, Tesson B, Gat E, Evrard S, Escudié F, Syrykh C, Canioni D, Fabiani B, Meignin V, Chassagne-Clement C, Dartigues P, Traverse-Glehen A, Parrens M, Huet S, Copie-Bergman C, Salles G, Birnbaum D, Brousset P, Morschhauser F, Xerri L; Lymphoma Study Association (LYSA). Laurent C, et al. Among authors: chassagne clement c. Am J Surg Pathol. 2021 Oct 1;45(10):1324-1336. doi: 10.1097/PAS.0000000000001726. Am J Surg Pathol. 2021. PMID: 34334687
Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.
Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maerevoet M, Salles G. Sarkozy C, et al. Blood. 2014 Apr 24;123(17):2740-2. doi: 10.1182/blood-2014-02-553693. Blood. 2014. PMID: 24764560 Free article. Clinical Trial. No abstract available.
Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.
Xerri L, Bachy E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Brousse N, Rousselet MC, Foussard C, Brice P, Feugier P, Morschhauser F, Sonet A, Olive D, Salles G; LYSA study. Xerri L, et al. Hum Pathol. 2014 Oct;45(10):2085-93. doi: 10.1016/j.humpath.2014.06.019. Epub 2014 Jul 17. Hum Pathol. 2014. PMID: 25149549 Free article. Clinical Trial.
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L. Laurent C, et al. Ann Oncol. 2016 Feb;27(2):306-14. doi: 10.1093/annonc/mdv575. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598546 Free PMC article.
Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas.
Broutier L, Creveaux M, Vial J, Tortereau A, Delcros JG, Chazot G, McCarron MJ, Léon S, Pangault C, Gadot N, Colombe A, Boulland ML, Blachier J, Marie JC, Traverse-Glehen A, Donzé O, Chassagne-Clément C, Salles G, Tarte K, Mehlen P, Castets M. Broutier L, et al. EMBO Mol Med. 2016 Feb 1;8(2):96-104. doi: 10.15252/emmm.201505480. EMBO Mol Med. 2016. PMID: 26882243 Free PMC article.
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Ribrag V, et al. Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11. Lancet. 2016. PMID: 27080498 Clinical Trial.
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK. Maurer MJ, et al. Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492. Epub 2016 Sep 3. Am J Hematol. 2016. PMID: 27465588 Free PMC article.
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G; a LYSA study. Xerri L, et al. Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13. Hum Pathol. 2017. PMID: 28414090 Clinical Trial.
53 results